Zenas BioPharma, Inc. (ZBIO) Stock Statistics & Valuation Metrics

Zenas BioPharma, Inc. has a market cap or net worth of $712.93M. The enterprise value is $133.40M.

Zenas BioPharma, Inc. has 42,110,313 shares outstanding. The number of shares has decreased by -2.65% in one year.

Zenas BioPharma, Inc.’s return on equity (ROE) is -0.50 and return on invested capital (ROIC) is -52.30%.

The current PE Ratio of Zenas BioPharma, Inc. is ―. Zenas BioPharma, Inc.’s PEG ratio is ―.

In the last 12 months, Zenas BioPharma, Inc. had revenue of 5.00M and earned -156.99M in profits. Earnings per share was -3.76.

In the last 12 months, operating cash flow was -148.41M and capital expenditures -92.00K, giving a free cash flow of -148.50M billion.

Zenas BioPharma, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Zenas BioPharma, Inc. upcoming earnings date is Aug 12, 2025, Before Open (Confirmed).

Zenas BioPharma, Inc. as a current ratio of 6.21, with Debt / Equity ratio of 0.42%

In the past 12 months, Zenas BioPharma, Inc. has paid 429.00K in taxes.

Zenas BioPharma, Inc. EV to EBITDA ratio is -0.14, with an EV/FCF ratio of -0.20.

Zenas BioPharma, Inc. has $273.28M in cash and marketable securities with $1.01M in debt, giving a net cash position of -$272.27M billion.

Gross margin is 99.68%, with operating margin of -3277.76%, and net profit margin of -3139.76%.

The average price target for Zenas BioPharma, Inc. is $29.90, which is 11.43% higher than the current price. The consensus rating is Strong Buy